| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Rasagiline | Allyl Amine | VL255003 | View CAS 107-11-9 |
| Rasagiline | Allyl Impurity | VL255001 | View CAS 1166392-42-2 |
| Rasagiline | N-(2-Chloroallyl)-1-(R)-aminoindan | VE0010129 | View CAS 1175018-73-1 |
| Rasagiline | Rasagiline 2-Chloro Allyl Impurity (Free base) | VL255002 | View CAS 1175018-73-1 |
| Rasagiline | Rasagiline 2-Chloro ally Impurity (Racemic Mixture) | VE006589 | View CAS 1179031-47-0 |
| Rasagiline | Rasagiline Dimer | VL255010 | View |
| Rasagiline | Rasagiline Impurity D | VE0010126 | View CAS 200628-33-7 |
| Rasagiline | Rasagiline Impurity IV | VL255012 | View |
| Rasagiline | Rasagiline Keto Impurity | VL255007 | View |
| Rasagiline | Rasagiline N-Allyl-1-indanamine | VE006588 | View CAS 91639-43-9 |
| Rasagiline | Rasagiline S-Isomer Mesylate salt | VL255011 | View CAS 202464-89-9 |
| Rasagiline | S-isomer of Rasagiline | VL255008 | View CAS 185517-74-2 |
| Rasagiline | Trans-N-(3-Chloroallyl)-1-(R)-aminoindan Hydrochloride | VE0010797 | View CAS 1175018-78-6 |
| Rasagiline | 1- Amino Indane | VL255005 | View CAS 10277-74-4 |
| Rasagiline | 1-Indanol | VL255006 | View CAS 25501-32-0 |
| Rasagiline | 1-Indanone | VL255004 | View CAS 83-33-0 |
| Rasagiline | 3-N-Propargylaminoindan-1-one Mesylate | VE006587 | View CAS 1312077-04-5 |
Rasagiline Related Compound
Rasagiline is an irreversible monoamine oxidase-B inhibitor that is used as a monotherapy or as an additional medication to treat symptoms in early Parkinson’s disease.
References
- “Rasagiline (Oral Route) Side Effects – Mayo Clinic.” Mayoclinic.org, 2023, www.mayoclinic.org/drugs-supplements/rasagiline-oral-route/side-effects/drg-20068415?p=1#:~:text=Rasagiline%20is%20used%20alone%20or,available%20with%20your%20doctor’s%20prescription. Accessed 13 Mar. 2023.
- “Rasagiline (Oral Route) Description and Brand Names – Mayo Clinic.” Mayoclinic.org, 2023, www.mayoclinic.org/drugs-supplements/rasagiline-oral-route/description/drg-20068415#:~:text=Rasagiline%20is%20used%20alone%20or,tremors%2C%20and%20slowed%20physical%20movement. Accessed 13 Mar. 2023.
- Finberg, John P. M. “Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential.” Rambam Maimonides Medical Journal, vol. 1, no. 1, June 2010, p. e0003, https://doi.org/10.5041/rmmj.10003. Accessed 13 Mar. 2023.
FAQ
What is the therapeutic use of rasagiline?
Rasagiline is used to treat Parkinson’s disease alone or in combination with levodopa. Parkinson’s disease is a progressive brain disorder that can cause movement issues, stiffness, tremors, and decreased physical mobility.
What type of medication is rasagiline?
Rasagiline is used to treat Parkinson’s disease alone or in combination with levodopa. Parkinson’s disease is a progressive brain disorder that can cause movement issues, stiffness, tremors, and decreased physical mobility.
What is the mechanism of action of rasagiline?
Rasagiline works as an anti-Parkinsonian agent by reducing the oxidative breakdown of DA in the striatum, and it can be used as a stand-alone treatment in the early stages of the illness or as an adjuvant to L-dopa in the later stages.
